Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says

25th July 2019 Uncategorised 0

It’s anybody’s guess about how the drug pricing debate will play out in Washington. But Bristol-Myers Squibb CEO Giovanni Caforio figures his company’s Celgene buy will fortify its position regardless of the result.

More: Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Source: fierce